Sanofi Launches Authorized Generic Version Of Arava Tablets

(RTTNews) - Sanofi US announced the availability of an authorized generic version of Arava, Leflunomide tablets through Winthrop, the company's US generics division. For people living with rheumatoid arthritis (RA), Leflunomide blocks autoimmune antibodies that reduce inflammation with the aim of improving mobility.

Sanofi's authorized generic version is the same formulation as the original drug, Arava, for which the company holds the original patent.

Rheumatoid arthritis is a chronic disease for which signs and symptoms can be lessened with treatment. Because joint damage is irreversible, early diagnosis and treatment are recommended.

Disease-modifying anti-rheumatic drugs or DMARDs such as Arava help to reduce signs and symptoms, inhibit structural damage as evidenced by X-Ray erosions and joint space narrowing and improve physical function. Since treatment is highly individualized based on patient response, Arava provides the ability to be used either alone or in combination with other DMARDs or biologics.